New drug duo aims to halt lung cancer growth
NCT ID NCT05017025
First seen Nov 19, 2025 · Last updated May 12, 2026 · Updated 22 times
Summary
This study tests whether adding an aurora kinase inhibitor to the standard drug osimertinib can better control advanced EGFR-mutant non-small cell lung cancer. About 32 adults with advanced or metastatic disease will receive the combination to find the safest dose and see if it slows tumor growth. The goal is to block enzymes that cancer cells need to multiply.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIIB LUNG CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.